Tenofovir-induced kidney injury

被引：31

作者：

Gitman, Michael D. ^{[1
]}

Hirschwerk, David ^{[1
]}

Baskin, Cindy H. ^{[1
]}

Singhal, Pravin C. ^{[1
]}

机构：

[1] Long Isl Jewish Med Ctr, Div Kidney Dis & Hypertens, New Hyde Pk, NY 11042 USA

来源：

EXPERT OPINION ON DRUG SAFETY | 2007年 / 6卷 / 02期

关键词：

Fanconi's syndrome; HIV; nucleotide reverse transcriptase inhibitor; renal failure; tenofovir;

D O I：

10.1517/14740338.6.2.155

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor with activity against both HIV and the hepatitis B virus. It has had minimal nephrotoxic effects in early clinical trials, but as clinical use has widened, case reports describing tenofovir-induced renal tubular damage, Fanconi's syndrome and diabetes insipidus have been described. The authors review the pharmacokinetics, mechanism of action and clinical uses of tenofovir disoproxil fumarate. The large clinical trials, as well as the case reports of tenofovir-induced kidney injury, are also reviewed. The potential mechanism of renal damage is discussed and recommendations for evaluation and treatment of tenofovir-induced kidney injury are given.

引用

页码：155 / 164

页数：10

共 71 条

[1] Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study [J].

Antoniou, T ;

Raboud, JM ;

Chirhin, S ;

Yoong, D ;

Govan, V ;

Gough, K ;

Rachlis, A ;

Loutfy, MR .

HIV MEDICINE, 2005, 6 (04) :284-290

[2] Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine [J].

Barrios, A ;

Rendón, A ;

Negredo, E ;

Barreiro, P ;

Garcia-Benayas, T ;

Labarga, P ;

Santos, J ;

Domingo, P ;

Sánchez-Conde, M ;

Maida, I ;

Martín-Carbonero, L ;

Núñez, M ;

Blanco, F ;

Clotet, B ;

Sambeat, MA ;

Gil, P ;

Gonzalez-Lahoz, J ;

Cooper, D ;

Soriano, V .

AIDS, 2005, 19 (06) :569-575

[3] Adefovir nephrotoxicity and mitochondrial DNA depletion [J].

Bendele, RA ;

Richardson, FC .

HUMAN PATHOLOGY, 2002, 33 (05) :574-574

[4] Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks [J].

Biesecker, G ;

Karimi, S ;

Desjardins, J ;

Meyer, D ;

Abbott, B ;

Bendele, R ;

Richardson, F .

ANTIVIRAL RESEARCH, 2003, 58 (03) :217-225

[5] Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors [J].

Birkus, G ;

Hitchcock, MJM ;

Cihlar, T .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :716-723

[6] Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy [J].

Buchacz, K. ;

Brooks, J. T. ;

Tong, T. ;

Moorman, A. C. ;

Baker, R. K. ;

Holmberg, S. D. ;

Greenberg, A. .

HIV MEDICINE, 2006, 7 (07) :451-456

[7] Tenoflovir disoproxil fumarate [J].

Antoniou, T .

DRUGS, 2003, 63 (15) :1609-1609

[8]

CICONI P, 2004, INT J ANTIMICROB AG, V24, P86

[9] Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors [J].

Cihlar, T ;

Birkus, G ;

Greenwalt, DE ;

Hitchcock, MJM .

ANTIVIRAL RESEARCH, 2002, 54 (01) :37-45

[10] Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs [J].

Cihlar, T ;

Ho, ES ;

Lin, DC ;

Mulato, AS .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) :641-648

← 1 2 3 4 5 6 7 8 →